Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Change in Cash (2023 - 2025)

Historic Change in Cash for Mereo BioPharma (MREO) over the last 3 years, with Q3 2025 value amounting to -$7.0 million.

  • Mereo BioPharma's Change in Cash rose 1360.78% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.7 million, marking a year-over-year decrease of 29282.09%. This contributed to the annual value of $12.4 million for FY2024, which is 21505.44% up from last year.
  • Mereo BioPharma's Change in Cash amounted to -$7.0 million in Q3 2025, which was up 1360.78% from -$7.8 million recorded in Q2 2025.
  • Over the past 5 years, Mereo BioPharma's Change in Cash peaked at $38.9 million during Q2 2024, and registered a low of -$9.7 million during Q4 2024.
  • Over the past 3 years, Mereo BioPharma's median Change in Cash value was -$7.8 million (recorded in 2025), while the average stood at -$1.9 million.
  • Over the last 5 years, Mereo BioPharma's Change in Cash had its largest YoY gain of 60576.3% in 2024, and its largest YoY loss of 16933.6% in 2024.
  • Mereo BioPharma's Change in Cash (Quarter) stood at -$5.1 million in 2023, then crashed by 89.76% to -$9.7 million in 2024, then increased by 27.69% to -$7.0 million in 2025.
  • Its Change in Cash stands at -$7.0 million for Q3 2025, versus -$7.8 million for Q2 2025 and -$8.2 million for Q1 2025.